Archives

Martin Knapp is Professor of Social Policy and Co-Director of LSE Health and Social Care at the London School of Economics. He is also Professor of Health Economics and Director of the Centre for the Economics of Mental Health at the Institute of Psychiatry, King’s College London. Since 2009, he has been Director of the NHIR School for Social Care Research in England.

For many years, Martin has been working in the fields of long-term care, mental health policy and practice, and health and social care policy more generally. Current activities include economic evaluations of a wide range of treatments and other interventions; studies of mental illness prevention and mental health promotion; examination of policies aimed at extending choice to patients and service users; and analyses of financing arrangements in health and social care systems.

He has been adviser on mental health and social care policy to many UK government departments and agencies (including the Prime Minister’s Strategy Unit, Department of Health, Department for International Development, Department for Work and Pensions, Department for Industry, Universities and Science), various quasi-governmental bodies, research charities, World Health Organization, World Bank and European Commission. From 2006 to 2007, he was Specialist Adviser to the House of Lords EU Select Committee inquiry on mental health.

Scientific publications

Publications include more than 350 articles in peer-review journals, about 150 chapters in edited volumes, 15 books and 4 edited books. Recent publications include:

  1. Adelina Comas-Hererra, Sarah Northey, Raphael Wittenberg, Martin Knapp, Sarmishtha Bhattacharyya and Alistair Burns (2010) Investigating future scenarios about the future prevalence and costs of cognitive impairment in older people, International Psychogeriatrics, forthcoming.
  2. Jose-Luis Fernandez, Julien Forder, Martin Knapp, (2010) Long-term care, in Peter Smith and Sherry Glied (editors) The Oxford Handbook of Health Economics, Oxford University Press, Oxford, forthcoming.
  3. Martin Knapp (2009) Mental well-being of older people: making an economic case (editorial), Australian eJournal for the Advancement of Mental Health, 8(2), 5pp.
  4. Paul McCrone, Sujith Dhanasiri, Anita Patel, Martin Knapp, Simon Lawton-Smith (2008) Paying the Price: The Cost of Mental Health Care in England to 2026, King’s Fund, London.
  5. Martin Knapp and Ami Somani (2008) Long-term care, organization and financing, in Harald Kristian Heggenhougen and Stella Quah (Editors) International Encyclopaedia of Public Health, volume 4, pages 133-141, Elsevier, New York.
  6. Martin Knapp, David McDaid, Elias Mossialos and Graham Thornicroft, editors (2007) Mental Health Policy and Practice across Europe, Open University Press, Buckingham.
  7. Adelina Comas-Herrera, Raphael Wittenberg, Linda Pickard and Martin Knapp (2007) Cognitive impairment in older people: the implications for future demand for long-term care services and their costs, International Journal of Geriatric Psychiatry, 22, 1037-1045.
  8. Robert J Howard, Edmund Juszczak, Clive Ballard, Peter Bentham, Richard Brown, Roger Bullock, Alistair Burns, Clive Holmes, Robin Jacoby, Tony Johnson, Martin Knapp, James Lindesay, John O’Brien, Gordon Wilcock, Cornelius Katona, Roy Jones, Julia DeCesare, Michaela Rodger and the CALM-AD Trial Group* (2007) Donepezil for the treatment of agitation in Alzheimer’s disease, New England Journal of Medicine, 357, 1382-1392.
  9. Martin Knapp (2007) Economic outcomes and levers: impacts for individuals and society, International Psychogeriatrics, 19, 483-495.
  10. Martin Knapp, Lene Thorgrimsen, Anita Patel, Aimee Spector, Angela Hallam, Bob Woods and Martin Orrell (2006) Cognitive stimulation therapy for people with dementia: cost-effectiveness analysis, British Journal of Psychiatry, 188, 574-580.

Specialist in Clinical Neurology and Preventive Medicine & Public Health, Jesús de Pedro Cuesta holds Spanish and Swedish citizenship and a Spanish and Swedish board-certificates in neurology. He was formally trained at the Karolinska Institute in social medicine and obtained a PhD degree in Health Services Research in 1986. For 1986-2005, he headed the Neuroepidemiology Unit at Huddinge University Hospital (Division of Neurology, Karolinska Institute). From 1994 to 2009 he was responsible for the Spanish National CJD Register. Major interest fields are epidemiology and services research on neurodegenerations including prion disorders and neuro-autoimmune diseases. Present position, since 1991: Head of the Department of Applied Epidemiology at the National Center for Epidemiology, Carlos III Institute of Health, Madrid, Spain. He has published approximately 150 epidemiological and health-services research papers in international peer-reviewed journals.

Scientific publications

  1. Gunnarsson LG, Lygner PE, de Pedro-Cuesta J, Veiga-Cabo J. An epidemic-like cluster of motor neuron disease in the County of Skaraborg, Sweden, 1973-1984. Neuroepidemiology 1996:15:142-152
  2. de Pedro-Cuesta J, Petersen IJ, Stawiarz L, Gudmundsson G, Gudmundsson G, Almazán J, Tulinius H, Johansson H. High levodopa use in periodically, time-clustered, Icelandic birth cohorts. A vestige of Parkinsonism etiology?. Acta Neurol Scand 1995:91:79-88
  3. de Pedro-Cuesta J, Gudmundssson G, Abraira V, Gudmundsson G, Almazán J, Veiga J, Tulinius H, Löve A. Whooping cough and Parkinson´s Disease. Int J Epidemiology. 1996:25:1301-1311
  4. I Zerr, M. Pocchiari, S Collins, JP Brandel, J. de Pedro Cuesta, RSG Knight, Bernheimer H, Cardone F, Delasnerie-Laupretre N, Cuadrado Corrales N, Ladogana A, Bodemer M, Fletcher A, Awan T, Ruiz Bremon A, Budka H, LaplancheJL, Will RG, Poser S. Analysis of EEG and CSF 14-3-3 proteins as aids to the diagnosis of Creutzfeldt-Jakob disease. Neurology 2000;55:811-5.
  5. Jin YP, de Pedro-Cuesta J, Söderström M. Predicting Multiple Sclerosis at Optic Neuritis Onset. Multiple Sclerosis 2003; 9: 135-141
  6. A Ladogana, M Puopolo, E Croes, H Budka, C Jarius, S Collins, C Masters, T Sutcliffe, A Guilivi, A Alperovitch, N Delasniere-Laupretre, J-P Brandel, S Poser, H Kretschmar, E Mitrova, J de Pedro Cuesta, P. Martinez-Martín, M Glatzel, A Aguzzi, R Knight, H Ward, M Pocchiari, C van Duijn, RG Will, I Zerr . Descriptive Epidemiology of Creutzfeldt-Jakob disease 1993-2000): The EUROCJD Collaborative study. Neurology 2005,65:1586-9129.
  7. de Pedro-Cuesta J, Bleda MJ, Rabano A, Cruz M, Laursen H, Molbak K, Siden A; on behalf of the EUROSURGYCJD Research Group. Classification of surgical procedures for epidemiologic assessment of sporadic Creutzfeldt-Jakob Disease transmission by surgery. Eur J Epidemiol. 2006;21:595-604.
  8. de Pedro-Cuesta J, Markus GlatzeL M, Almazan J, Stoeck K, Mellina V, Puopolo M, Pocchiari M, Zerr I, Kretzschmar HA, Brandel JP, Delasnerie-Laupretre N, Alperovitch A, van Duijn C, Sanchez-Juan P, Collins S, Lewis V, Jansen GH, Coulthart MB, Gelpi E, Budka H and Mitrova E. Human transmissible spongiform encephalopathies in eleven countries: diagnostic pattern across time, 1993-2002. BMC Public Health 2006,
  9. Mahillo-Fernandez I, De Pedro Cuesta J, Bleda MJ, Cruz M, Mølbak K, Laursen H, Falkenhorst G, Martínez-Martín P, Siden Å. Surgery and risk of sporadic Creutzfeldt-Jakob disease in Denmark and Sweden: registry-based case-control studies. Neuroepidemiology, 2008, 2008; 31:229-40

Dr Philip Scheltens studied at the Vrije Universiteit Amsterdam, Netherlands, gaining his MD in 1984, and PhD (magnetic resonance imaging in Alzheimer’s disease) in 1993. Clinical residencies in neurosurgery at the Municipal Hospital Slotervaart, and at the Vrije Universiteit Medical Centre, Amsterdam, as well as an associate professorship at Karolinska Institute, supported his academic development. Since 2000, Dr Scheltens is Professor of Cognitive Neurology and Director of the Alzheimer Center at the VU University Medical Center in Amsterdam. His main clinical and research interests are Alzheimer’s disease, vascular dementia, frontotemporal dementia, structural and functional imaging and CSF biomarkers.

Dr Scheltens is an active member of several societies including the Dutch Society for Neurology, the International Psychogeriatric Association, the American Academy of Neurology, the Alzheimer Imaging Consortium, the European Alzheimer’s Disease Consortium and the European College of Neuropsychopharmacology. He was associate editor of the Journal of Neurology, Neurosurgery and Psychiatry until 2010, book review editor of Alzheimer Disease and Associated Disorders as well as member of the editorial boards of Dementia and Geriatric Cognitive Disorders, Journal of NeuroImaging and International Journal of Geriatric Psychiatry, and acts as an ad hoc reviewer of scientific articles for, amongst others, The Lancet Neurology, Stroke, Journal of Neurology, Neurology, JNNP, Brain, Annals of Neurology and Science. He is a member of the scientific advisory panel of the French Plan Alzheimer, member of the Scientific advisory board of the Joint Programming Neurodegeneration and treasurer of the International Society for Vascular Behavioural and Cognitive Disorders (Vas-Cog).

Honours and Awards

  • 1998 Medaille d’Or Universiteit Lille.
  • 1997-98 Visiting Professor Karolinska Institute, Stockholm, Zweden.
  • 1998-99 Visiting Professor Institute for the Health of the Elderly, Newcastle upon Tyne, UK
  • 2000 Membre d’honeur a titre etranger de Societe Francaise de Neurologie.
  • 2004 Visiting Professor, University of British Columbia, Canada
  • 2008-2013 Honorary Professor of Neurology, University College of London, Institute of Neurology, Queen Square

Scientific publications

More than 406 publications in peer reviewed journals, >550 scientific abstracts and many chapters in national and international books, as well as co-editor of the book Magnetic Resonance in Dementia (Springer) 2002 and co-editor of the book Clinical applications of fMRI (Oxford University Press).

Selected recent publications

  1. Frisoni GB, Fox NC, Jack CR Jr, Scheltens P, Thompson PM. The clinical use of structural MRI in Alzheimer disease. Nat Rev Neurol 2010;6:67-77.
  2. Scheltens P, Kamphuis PJGH, Verhey FRJ, Olde Rikkert MGM, Wurtman RJ, Wilkinson D, Twisk JWR, Kurz A. Efficacy of a medical food in mild Alzheimer’s disease: a randomized, controlled trial. Alzheimers Dement 2010;6:1-10
  3. Bouwman FH, Schoonenboom NSM, Verwey NA, van Elk EJ, Kok A, Blankenstein MA, Scheltens P, van der Flier WM. CSF biomarker levels in early and late onset Alzheimer’s disease. Neurobiol Aging 2009;30:1895-1901.
  4. Goos JDC, Kester MI, Barkhof F, Klein M, Blankenstein MA, Scheltens P, van der Flier WM. Patients with Alzheimer disease with multiple microbleeds. Relation with cerebrospinal fluid biomarkers and cognition. Stroke 2009;40:3455-3460.
  5. Inzitari D, Pracucci G, Poggesi A, Carlucci G, Barkhof F, Chabriat H, Erkinjuntti T, Fazekas F, Ferro JM, Hennerici M, Langhorne P, O’Brien J, Scheltens P, Visser MC, Wahlund LO, Waldemar G, Wallin A, Pantoni L, on behalf of the LADIS Study Group. Changes in white matter as determinant of global functional decline in older independent outpatients: three year follow-up of LADIS (leukoaraiosis and disability) study cohort. BMJ 2009;339:b2477

Professor Bengt Winblad, MD, PhD has been involved in the field of dementia research for many years. He became MD 1971 and took his PhD in 1975 at the University of Umeå, Sweden, where he became a Docent in 1977 and Professor of Geriatric Medicine and Chief Physician in 1982. Bengt Winblad has since been a guest professor at the Department of Psychiatry in Frankfurt and honorary professor at Beijing University, Wuhan University and Shanghai University in China. Currently, he is working in Stockholm, Sweden as Professor of Geriatric Medicine at the Karolinska Institutet and is Chief Physician at Karolinska University in Huddinge.

Professor Winblad has been involved in numerous professional appointments and university activities. These have included being a member of the Advisory Committee for the Medical Research Council. He is co-chairing the European Alzheimer Disease Consortium (EADC) and presently chairing the Medical Scientific Advisory Panel of the Alzheimer Disease International (ADI). He is also a member of the Nobel Assembly for the Prize of Medicine and Physiology at the Karolinska Institutet. Professor Winblad is the Head of the KI-Alzheimer Disease Research Center in Huddinge including KASPAC (KI Dainippon Sumitomo Alzheimer Center), as well as the Director of the Swedish Brain Power research network.

Bengt Winblad’s research interests focus on the epidemiology, genetics and treatment of dementia conditions, especially Alzheimer’s disease. He has been presented with a number of awards for his contribution to this research area. He has taken the initiative regarding pharmaceutical treatment (memantine and later donepezil) of patients with severe Alzheimer’s disease. Professor Winblad has been a tutor for more than 150 PhD dissertations and has published more than 1000 original publications in the field of gerontology/geriatrics/dementia research.

Honours and Awards

  • 1997 The Royal Swedish Academy of Medical Sciences Award for Dementia Research
  • 1997 Norage Kabi Pharmacia Awards
  • 1997 The Alois Alzheimer Award
  • 1997 Honorary Professor, Beijing University of Medical Science
  • 2001 The Swedish Society of Medicine Award (Sandeborg’s price)
  • 2001 Swedish Medical Society (Thuréus prize)
  • 2001 Honorary Professor, Wuhan University of Medical Science
  • 2002 The Nordic Prize in Gerontology
  • 2002 Honorary Professor, University of Timisoara, Romania
  • 2005 IPA Recognition Award for Service to the Field of Psychogeriatrics
  • 2006 Honorary Professor, Jiao-Tong University, Shanghai
  • 2008 Award established in my name by the organisation International Conf in AD and related disorders (ICAD) “Khalid Iqbal and Bengt Winblad Lifetime Achievement Awards in AD” to be given out every year at ICAD conferences.

Five selected scientific publications

  • Mullan M, Crawford F, Axelman K, Houlden H, Lilius L, Winblad B, Lannfelt L. A pathogenic mutation for probable Alzheimer’s disease in the APP gene at the N-terminus of beta-amyloid. Nature Genetics. 1992, 1: 345-347
  • Winblad B, Poritis N. Memantine in severe dementia: Results of the 9M-best study (benefit and efficacy in severely demented patients during treatment with Memantine). Int J Ger Psych 1999: 14: 135-146
  • Winblad B, Palmer K, Kivipelto M. Jelic V, Fratiglioni L, Wahlund L-O, Nordberg A, Bäckman L, Albert M, Almkvist O, Arai H, Basun H, Blennow K, De Leon M, Decarli C, Erkinjuntti T, Giacobine E, Graff C, Hardy J, Jack C, Jorm A, Ritchie K, Van Duijn C, Visser PJ, Petersen R. Mild cognitive impairment: beyond controversies, towards a consensus: report of the International working group on mild cognitive impairment, J Internal Med 2004; 256; 240-246
  • Winblad B, Kilander L, Eriksson S, Minthon L, Båtsman S, Wetterholm A-L, Jansson-Blixt C, Haglund A, Donepezil in patients with severe Alzheimer´s disease: double-blind, parallel-group, placebo-controlled study. Lancet, 2006; 367(9516): 1057-65.5
  • Winblad B, Cummings J, Anderasen N, Grossberg G, Onofrj M, Sadowsky C, Zechner S, Nagel J, Lane R, A six-month double-blind, randomized, placebo-controlled study of a transdermal patch in Alzheimer’s disease–rivastigmine patch versus capsule. Int J Geriatr Psych. 2007;22(5):456-67.